The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an autoantibody, vectors comprising the same, compositions comprising CAAR vectors packaged in viral particles, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified T cell expressing a CAAR (CAART) wherein the expressed CAAR comprises a desmoglein extracellular domain.

An application of a combination of SIRT1-7 protein or CD258 protein and SIRT1-7 protein for promoting immune cell proliferation is provided.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The present invention provides an immunoconjugate having the formula: T-c-E.sub.n-c-Fc.sub.n or T-c-Fc.sub.n-c-E.sub.n; wherein, T is a single chain variable portion fragment of a monoclonal antibody (scFv) directed to a target protein, polypeptide, or fragment thereof, which is highly expressed on cancer cells; E is two or more foreign immunogenic CD8.sup.+ T cell antigenic epitopes; c is a peptide or polypeptide fragment thereof, capable of being cleaved by a specific protease; and Fc is two or more Fc portions of an IgG antibody. Nucleic acid sequences encoding the same and vectors containing said nucleic acid sequences are also provided. Methods of making the immunoconjugate, along with methods of making target cells susceptible to CTL mediated cell killing, and methods for treatment of cancers are also provided.

The present invention relates to a chimeric antigen receptor including a CD30-derived intracellular signaling domain, immune cells expressing same, and uses thereof. More specifically, the present invention is designed to use a chimeric antigen receptor including a portion of the sequence of TRAF-binding domain within the CD30 domain as an intracellular signaling domain to increase the proliferation and survival of immune effector cells, thereby providing an effect of enhancing antitumor efficacy and cytokine secretion.

Provided herein are novel anti-LHR chimeric antigen receptor (CAR), cells or compositions comprising the same, vector or plasmid encoding anti-LHR CAR, and methods for producing the same, or using the same for detecting or treating ovarian cancer or prostate cancer. Also provided herein are anti-LHR antibody, compositions comprising the same, nucleic acid sequence encoding the same, and a kit for detecting LHR.

The present invention relates to mesothelin-specific antibody and uses thereof, and more particularly to antibody that specifically bind to mesothelin, chimeric antigen receptors comprising the antibody, CAR-T cells expressing the chimeric antigen receptors, and a pharmaceutical composition for the prevention or treatment of mesothelin-expressing cancers or tumors comprising the antibody.

Seven antibodies specific to mesothelin (3A8, 4G11, 5A9, 6G5, 7C3, 9E8, and 9E11) selected in the present invention were found to specifically bound to mesothelin antigen and enable the preparation of chimeric antigen receptor (CAR) and CAR-T cells (MSLN-CAR-T cells) targeting mesothelin. Furthermore, we have confirmed that the MSLN-CAR-T cells produced by the present invention activate MSLN-CAR-T cells in the presence of mesothelin antigen and effectively killed cells overexpressing mesothelin, so that the antibodies specific for mesothelin and the chimeric antigen receptors and CAR-T cells produced using the same can be applied to the prevention or treatment of cancer or tumors in which mesothelin is overexpressed.

The invention provides compositions and methods for treating diseases associated with expression of EGFRvIII. The invention also relates to chimeric antigen receptor (CAR) specific to EGFRvIII, vectors encoding the same, and recombinant T cells comprising the anti-EGFRvIII CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an anti-EGFRvIII binding domain.

The present disclosure provides a heterodimeric, conditionally active chimeric antigen receptor (CAR), and a nucleic acid comprising a nucleotide sequence encoding the CAR. The present disclosure provides cells genetically modified to produce the CAR. A CAR of the present disclosure can be used in various methods, which are also provided.

Provided are systems for modifying a cell. Also provided are methods for using the systems for modifying a cell.